Blood Plasma Pseudocholinesterase as a Potential Biomarker of Autoimmune Diseases


如何引用文章

全文:

开放存取 开放存取
受限制的访问 ##reader.subscriptionAccessGranted##
受限制的访问 订阅存取

详细

We studied the blood plasma butyrylcholinesterase (BChE, pseudocholinesterase) activity as a potential marker for differentiating such autoimmune pathologies as type 1 diabetes mellitus (DM1), autoimmune thyroiditis (AIT) and rheumatoid arthritis (RA) from diseases having similar symptoms but different etiology. The blood plasma pseudocholinesterase activity was analyzed for patients with different types of diabetes mellitus. We showed its fivefold increase in DM1 compared to the control group, while in the second type of diabetes, which is metabolic pathology, it decreases two times. It was demonstrated that the activity of blood plasma BChE in patients with AIT and RA also increased fivefold compared to the group of patients without autoimmune disorders. Thus, the butyrylcholinesterase activity increases in diseases of an autoimmune nature, whereas in metabolic pathology it has the tendency to decrease; it indicates the adequacy of the selected criterion for the further development of a screening test-system that would allow differentiation of autoimmune diseases from the diseases of another origin, but with similar symptoms.

作者简介

D. Kozlova

ABRIS+ Ltd.; Sechenov Institute of Evolutionary Physiology and Biochemistry

编辑信件的主要联系方式.
Email: KozlovaDI@abrisplus.ru
俄罗斯联邦, St. Petersburg, 196084; St. Petersburg

A. Popov

ABRIS+ Ltd.

Email: KozlovaDI@abrisplus.ru
俄罗斯联邦, St. Petersburg, 196084

D. Vasilyev

ABRIS+ Ltd.; Sechenov Institute of Evolutionary Physiology and Biochemistry

Email: KozlovaDI@abrisplus.ru
俄罗斯联邦, St. Petersburg, 196084; St. Petersburg

E. Suglobova

ABRIS+ Ltd.; Pavlov First St. Petersburg State Medical University

Email: KozlovaDI@abrisplus.ru
俄罗斯联邦, St. Petersburg, 196084; St. Petersburg

V. Markovskiy

ABRIS+ Ltd.

Email: KozlovaDI@abrisplus.ru
俄罗斯联邦, St. Petersburg, 196084

补充文件

附件文件
动作
1. JATS XML

版权所有 © Pleiades Publishing, Ltd., 2018